Wednesday, July 31, 2024 7:46:42 AM
Recent RNAZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/28/2024 08:02:18 PM
- TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data • GlobeNewswire Inc. • 10/23/2024 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/15/2024 09:23:29 PM
- TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:02:19 PM
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 10:02:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:04:03 PM
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:45:28 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/26/2024 08:05:13 PM
- TransCode Therapeutics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 07/24/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 01:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 12:18:22 PM
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 07/23/2024 02:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 08:10:38 PM
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 07/22/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:16:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 12:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:06:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/10/2024 12:45:13 PM
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements • GlobeNewswire Inc. • 06/10/2024 11:00:00 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM